S&P Futures
5,889.25 -3.25 (-0.06%) Dow Futures
43,050.00 -119.00 (-0.28%) Nasdaq Futures
20,524.00 -18.00 (-0.09%) Russell 2000 Futures
2,244.80 -1.40 (-0.06%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.20 -6.60 (-0.24%)
Galera Therapeutics, Inc. (GRTX)
| Previous Close | 0.0555 |
| Open | 0.0531 |
| Bid | 0.0552 x 0 |
| Ask | 0.0600 x 0 |
| Day's Range | 0.0531 - 0.0553 |
| 52 Week Range | 0.0510 - 0.2900 |
| Volume | |
| Avg. Volume | 325,942 |
| Market Cap | 3.005M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireGalera Announces Board Approval of Complete Liquidation and Dissolution
Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company unde
- GlobeNewswire
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder valueMALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of
